semaglutide advisory committee Wegovy (semaglutide) is a step closer to being subsidised in Australia, after the Pharmaceutical Benefits (PBAC) recommended it be listed on the PBS for some adults living with obesity and Attention Healthcare professionals: WHO Issues

Given strong consumer interest in GLP1 therapies, companies using digital or social-media marketing may want to consider substantiation, balanced messaging, and clear disclosure of material connections

Murugan R, Tamil Selvan S, Dharmalingam Jothinathan MK, Srinivasan GP, Rajan Renuka R, Prasad M

The structure of the GLP-1 receptor complexed with its ligand offers insight into the mechanism of class B G-protein-coupled receptor activation.

Now that the FDA has shut the door on mass compounded semaglutide, this is the most affordable and safest way to get started on a real FDA approved GLP-1

64% at 1 year and 84% at 2 years in those without diabetes Risk factors of discontinuation include lower income, older age, lower weight loss, cost, among others

Sermorelin supports long-term vitality by encouraging natural HGH production